COHANCE · Health Care · 2026-08-07

Cohance Lifesciences Ltd

Stage 4 · wk 2MARKET: BULL TOPPING · 2026-08-07
₹445.8
+1.56% today
₹17,054 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Visit company website →
P/E (TTM)
91.2
Forward 33.3
Earnings Growth (YoY)
-70.3%
Revenue +77.3%
vs 52W High
-56.3%
₹279.9 lo₹1,019.8 hi
56.3% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 2
1w13w26w
Week 2 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-3.5%
200 DMA: ₹461.8 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.51x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -2.1% vs MA50 -1.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-05-08 → 2026-08-07
S? 41w
S4 10w
S1 13w
2025-05-082026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S4 10w → S1 13w → S4 1w current
Total tracked: 65 weeks across 4 stage runs.
1M
+1.3%
3M
-8.7%
6M
+20.2%
YTD
-17.0%
1Y
-55.9%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-08-07S4
Wk 2 · Vol —x
2026-08-06S4
Wk 1 · Vol —x
2026-08-05S4
Wk 1 · Vol —x
2026-08-04S4
Wk 1 · Vol —x
2026-08-03S4
Wk 1 · Vol —x
2026-07-31S41→4
Wk 1 · Vol —x
2026-07-30S1
Wk 13 · Vol —x
2026-07-29S1
Wk 13 · Vol —x
2026-07-28S1
Wk 12 · Vol —x
2026-07-27S1
Wk 12 · Vol —x
2026-07-24S1
Wk 12 · Vol —x
2026-07-23S1
Wk 12 · Vol —x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹435.2
200 DMA
₹461.8
52W High
₹1,019.8
52W Low
₹279.9
5D Low
₹424.9
Resistance levels (recent highs)
20d High
₹450.7
60d High
₹462.4
120d High
₹493.3
250d High
₹1,019.8
Next resistance
+1.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.